Burden of illness of chemotherapy in castration-resistant prostate cancer patients in Japan: a retrospective database analysis

References

• National Cancer Center. Cancer statistics 2016. Available at: http://ganjoho.jp/reg_stat/statistics/stat/summary.html [Last accessed 27 April 2017]
   Google Scholar
• Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Canc 2015;136:E359-86
   PubMed Web of Science ®Google Scholar
• Kitazawa T, Matsumoto K, Fujita S, et al. Cost of illness of the prostate cancer in Japan – a time–trend analysis and future projections. BMC Health Serv Res 2015;15:453
   PubMed Web of Science ®Google Scholar
• National Cancer Center. Cancer incident rate 2017. Available at: http://ganjoho.jp/reg_stat/statistics/stat/summary.html [Last accessed 27 April 2017]
   Google Scholar
• Tannock I, de Wit R, Berry W, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502-12
   PubMed Web of Science ®Google Scholar
• Anderson J. The need for improved therapeutic strategies for patients with metastatic hormone-refractory prostate cancer. Eur Urol Suppl 2006;30;5:811-16
   Web of Science ®Google Scholar
• van Soest RJ, de Wit R. Irrefutable evidence for the use of docetaxel in newly diagnosed metastatic prostate cancer: results from the STAMPEDE and CHAARTED trials. BMC Med 2015;13:304
   PubMed Web of Science ®Google Scholar
• Miller RE, Sweeney CJ. Chemotherapy for metastatic castrate-sensitive prostate cancer. Prostate Canc Prostatic Dis 2016;19:139-44
   PubMed Web of Science ®Google Scholar
• Miyake H, Sakai I, Terakawa T, et al. Oncological outcome of docetaxel-based chemotherapy for Japanese men with metastatic castration-resistant prostate cancer. Urol Oncol: Seminars and Original Investigations 2013;31:733-8
   PubMed Web of Science ®Google Scholar
• American Cancer Society. Chemotherapy for Prostate Cancer. Available at: https://www.cancer.org/cancer/prostate-cancer/treating/chemotherapy.html accessed on April 26, 2017
   Google Scholar
• Hassett MJ, O’malley AJ, Pakes JR, et al. Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer. J Natl Canc Inst 2006;98:1108-17
   PubMed Web of Science ®Google Scholar
• Russo A, Autelitano M, Bisanti L. Re: Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer. J Natl Canc Inst 2006;98:1826-7
   PubMedGoogle Scholar
• Alemayehu B, Buysman E, Parry D, et al. Economic burden and healthcare utilization associated with castration-resistant prostate cancer in a commercial and Medicare Advantage US patient population. J Med Econ 2010;13:351-61
   PubMedGoogle Scholar
• Grabner M, Onukwugha E, Jain R, et al. Racial variation in the cost-effectiveness of chemotherapy for prostate cancer. J Oncol Pract 2011;7:e16-24s
   Google Scholar
• Armstrong A, Bui C, Fitch K, et al. Docetaxel chemotherapy in metastatic castration-resistant prostate cancer: cost of care in Medicare and commercial populations. Curr Med Res Opin 2017;20:1-7
   Google Scholar
• Kunisawa S, Tange C, Shimozuma K. Realities in cost-effectiveness analyses: a study of castration-resistant prostate cancer patients using a medical claims database, SpringerPlus 2015;4:624
   PubMed Web of Science ®Google Scholar
• Neupane S, Bray F, Auvinen A. National economic and development indicators and international variation in prostate cancer incidence and mortality: an ecological analysis. World J Urol 2017;35(6):851-858
   PubMed Web of Science ®Google Scholar
• Saokaew S, Sugimoto T, Kamae I, et al. Healthcare databases in Thailand and Japan: potential sources for health technology assessment research. PLoS One 2015;10:e0141993
   PubMed Web of Science ®Google Scholar
• Wang K, Li P, Chen L, et al. Impact of the Japanese diagnosis procedure combination-based payment system in Japan. J Med Syst 2010;34:95-100
   PubMed Web of Science ®Google Scholar
• Sruamsiri R, Ferchichi S, Jamotte A, et al. Impact of patient characteristics and treatment procedures on hospitalisation cost and length of stay in Japanese Patients with influenza: a structural equation modelling approach. Influenza Other Respir Viruses 2017;11:543-55
   PubMed Web of Science ®Google Scholar
• Cheung S, Hamuro Y, Mahlich J, et al. Drug utilization of Japanese patients diagnosed with schizophrenia: an administrative database analysis. Clin Drug Investig 2017;37:559-69
   PubMed Web of Science ®Google Scholar
• Mahlich J, Sruamsiri R. Treatment patterns of rheumatoid arthritis in Japanese hospitals and predictors of the initiation of biologic agents. Curr Med Res Opin 2017;33:101-7
   PubMed Web of Science ®Google Scholar
• Mahlich J, Sruamsiri R. Persistence with biologic agents for the treatment of rheumatoid arthritis in Japan. Patient Prefer Adherence 2016;10:1509-19
   PubMed Web of Science ®Google Scholar
• Hallas J. Evidence of depression provoked by cardiovascular medication: a prescription sequence symmetry analysis. Epidemiology 1996;7:478-84
   PubMed Web of Science ®Google Scholar
• Wahab IA, Pratt NL, Wiese MD, et al. The validity of sequence symmetry analysis (SSA) for adverse drug reaction signal detection. Pharmacoepidemiol Drug Saf 2013;22:496-502
   PubMed Web of Science ®Google Scholar
• PMDA. Report of pilot study regarding potential methods to evaluate expression risk with receipt data. Available at: https://www.pmda.go.jp/files/000204928.pdf [Last accessed 11 May 2017]
   Google Scholar
• Grabner M, Onukwugha E, Mullins C, et al. Who receives chemotherapy: an analysis of stage IV prostate cancer (PCa) patients in SEER-Medicare. J Clin Oncol 2010;28:15(suppl):4655
   Google Scholar
• Chin SN, Wang L, Moore M, Sridhar SS. A review of the patterns of docetaxel use for hormone-resistant prostate cancer at the Princess Margaret Hospital. Curr Oncol 2010;17:24-9
   PubMed Web of Science ®Google Scholar
• Italiano A, Ortholan C, Oudard S, et al. Docetaxel-based chemotherapy in elderly patients (age 75 and older) with castration-resistant prostate cancer. Eur Urol 2009;55:1368-76
   PubMed Web of Science ®Google Scholar
• Onukwugha E, Mullins CD, Hsu VD, et al. Effect of urologists and medical oncologists on treatment of elderly men with stage IV prostate cancer. Urology 2011;77:1088-95
   PubMed Web of Science ®Google Scholar
• Repetto L. Greater risks of chemotherapy toxicity in elderly patients with cancer. J Support Oncol 2003;1(4 Suppl 2):18-24
   PubMedGoogle Scholar
• Package insert of docetaxel. Available at: http://www.pmda.go.jp/PmdaSearch/iyakuDetail/780069_4240405A1037_1_07#183 [Last accessed 11 May 2017]
   Google Scholar
• NICE. Prostate cancer: diagnosis and management. London, 2014. Available at: https://www.nice.org.uk/guidance/CG175 [Last accessed 11 May 2017]
   Google Scholar
• Templeton AJ, Vera-Badillo FE, Wang L, et al. Translating clinical trials to clinical practice: outcomes of men with metastatic castration resistant prostate cancer treated with docetaxel and prednisone in and out of clinical trials. Ann Oncol 2013;24:2972-7
   PubMed Web of Science ®Google Scholar
• Mehra M, Wu Y, Dhawan R. Healthcare resource use in advanced prostate cancer patients treated with docetaxel. J Med Econ 2012;15:836-43
   PubMedGoogle Scholar
• Alemayehu B, Buysman E, Parry D, et al. Economic burden and healthcare utilization associated with castration-resistant prostate cancer in a commercial and Medicare Advantage US patient population. J Med Econ 2010;13(2):351-61.
   Google Scholar
• Reinhardt UE, Hussey PS, Anderson GF. U.S. health care spending in an international context. Health Affairs 2004;23:10-25
   Web of Science ®Google Scholar
• Philipson T, Eber M, Lakdawalla DN, et al. An analysis of whether higher health care spending in the United States versus Europe is “worth it” in the case of cancer. Health Affairs 2012;31:667-75
   Web of Science ®Google Scholar
• Schaede U, Mahlich J, Nakayama M, et al. Shared decision-making in prostate cancer treatment in Japan: patient preferences versus physician perceptions. J Global Oncol 2018;4:1-9
   PubMed Web of Science ®Google Scholar